Mladen Korbelik

Prof. Dr. Mladen Korbelik

BC Cancer
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2011 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
PAPatrizia Agostinis
Patrizia Agostinis
Kristian BergKristian Berg
Kristian Berg
KCKeith A. Cengel
Keith A. Cengel
TFThomas H. Foster
Thomas H. Foster
Albert GirottiAlbert Girotti
Albert Girotti
JGJakub Golab
Jakub Golab
CA: A Cancer Journal for Clinicians publishes information about the prevention, early detection, and treatment of cancer, as well as nutrition, palliative care, survivorship, and additional topics of interest related to cancer care.

21 April 2006 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
MKMladen Korbelik
Mladen Korbelik

5 June 2011 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MKMladen Korbelik
Mladen Korbelik
WZWei Zhang
Wei Zhang
SMSoroush Merchant
Soroush Merchant

8 October 2005 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MKMladen Korbelik
Mladen Korbelik
JSJinghai Sun
Jinghai Sun

24 January 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IHIrati Beltrán Hernández
Irati Beltrán Hernández
YYYingxin Yu
Yingxin Yu
FOFerry Ossendorp
Ferry Ossendorp
MKMladen Korbelik
Mladen Korbelik
SOSabrina Oliveira
Sabrina Oliveira
Photodynamic therapy (PDT) is an anticancer strategy utilizing light-mediated activation of a photosensitizer (PS) which has accumulated in tumor and/or surrounding vasculature. Upon activation, the PS mediates tumor destruction through the generation of reactive oxygen species and tumor-associated vasculature damage, generally resulting in high tumor cure rates. In addition, a PDT-induced immune response against the tumor has been documented in several studies. However, some contradictory results have been reported as well. With the aim of improving the understanding and awareness of the immunological events triggered by PDT, this review focuses on the immunological effects post-PDT, described in preclinical and clinical studies. The reviewed preclinical evidence indicates that PDT is able to elicit a local inflammatory response in the treated site, which can develop into systemic antitumor immunity, providing long-term tumor growth control. Nevertheless, this aspect of PDT has barely been explored in clinical studies. It is clear that further understanding of these events can impact the design of more potent PDT treatments. Based on the available preclinical knowledge, recommendations are given to guide future clinical research to gain valuable information on the immune response induced by PDT. Such insights directly obtained from cancer patients can only improve the success of PDT treatment, either alone or in combination with immunomodulatory approaches.

30 October 2007 in British Journal of Cancer
Verified
Journal Article
Open access
MKMladen Korbelik
Mladen Korbelik
BSB Stott
B Stott
JSJ Sun
J Sun
Recent investigations have established that tumour cells treated in vitro by photodynamic therapy (PDT) can be used for generating potent vaccines against cancers of the same origin. In the present study, cancer vaccines were prepared by treating mouse SCCVII squamous cell carcinoma cells with photosensitiser chlorin e6-based PDT and used against poorly immunogenic SCCVII tumours growing in syngeneic immunocompetent mice. The vaccine potency increased when cells were post-incubated in culture after PDT treatment for 16 h before they were injected into tumour-bearing mice. Interfering with surface expression of phosphatidylserine (annexin V treatment) and apoptosis (caspase inhibitor treatment) demonstrated that this post-incubation effect is affiliated with the expression of changes associated with vaccine cell death. The cured mice acquired resistance to re-challenge with the same tumour, while the engagement of cytotoxic T lymphocytes was demonstrated by detection of high numbers of degranulating CD8+ cells in vaccinated tumours. The vaccines prepared from ex vivo PDT-treated SCCVII tumour tissue were also highly effective, implying that surgically removed tumour tissue can be directly used for PDT vaccines. This opens attractive prospects for employing PDT vaccines tailored for individual patients targeting specific antigens of the patient's tumour.